Difference between revisions of "Team:NCKU Tainan/Demonstrate"
| (4 intermediate revisions by 2 users not shown) | |||
| Line 50: | Line 50: | ||
</div> | </div> | ||
<br><br> | <br><br> | ||
| − | <p> Our device, <b>CreSense</b> consists of three major parts: a centrifugal platform for | + | <p> Our device, <b>CreSense</b> consists of three major parts: a centrifugal platform for plasma separation, a fluorescence intensity reader and a WiFi-module to monitor the fluorescence intensity online. In this section, we will demonstrate how our blood <i>p</i>-Cresol reader works.</p> |
| − | <p> Whole blood is injected into our <a href="https://2019.igem.org/Team:NCKU_Tainan/Hardware#Subtitle3" target="_blank">microfluidic chip</a>. All the user needs to do is to press a button to start the blood centrifugation. After approximately 15 minutes, the blood will be separated into two layers. | + | <p> Whole blood is injected into our <a href="https://2019.igem.org/Team:NCKU_Tainan/Hardware#Subtitle3" target="_blank">microfluidic chip</a>. All the user needs to do is to press a button to start the blood centrifugation. After approximately 15 minutes, the blood will be separated into two layers. Plasma will flow into the reaction chamber and react with our <i>p</i>-Cresol sensing bacteria. Then, the <a href="https://2019.igem.org/Team:NCKU_Tainan/Hardware#Subtitle4" target="_blank">reader</a> will show the real time fluorescence intensity reading on the LCD screen and simultaneously uploaded to an <a href="https://2019.igem.org/Team:NCKU_Tainan/Hardware#Database" target="_blank">online database</a>.</p> |
<p> This device is meant to be placed in the diagnostic center and other healthcare service providers. However, this device is not limited to just patients who take our live therapeutic. Patients who are concerned about their health or is at a high risk of developing chronic kidney disease may also use this device as a preventative measure.</p> | <p> This device is meant to be placed in the diagnostic center and other healthcare service providers. However, this device is not limited to just patients who take our live therapeutic. Patients who are concerned about their health or is at a high risk of developing chronic kidney disease may also use this device as a preventative measure.</p> | ||
<p> To demonstrate our engineered system works, we have made a video to explain each part of <b>CreSense</b> and the operating process.</p> | <p> To demonstrate our engineered system works, we have made a video to explain each part of <b>CreSense</b> and the operating process.</p> | ||
| Line 122: | Line 122: | ||
<figure class="d-flex flex-column justify-content-center align-items-center px-lg-3"> | <figure class="d-flex flex-column justify-content-center align-items-center px-lg-3"> | ||
<!-- put link in href & src , width in a can adjust--> | <!-- put link in href & src , width in a can adjust--> | ||
| − | <a href="https://static.igem.org/mediawiki/2019/ | + | <a href="https://static.igem.org/mediawiki/2019/archive/e/ec/20191021144634%21T--NCKU_Tainan--can-plate.png" target="_blank" style="width:90%"><img src="https://static.igem.org/mediawiki/2019/archive/e/ec/20191021144634%21T--NCKU_Tainan--can-plate.png" alt="" title="" style="width:100%"></a> |
| − | <figcaption>Fig. 5. Confirmation of <i>can</i> knockout in <i>E. coli</i> Nissle. <i>E. coli</i> Nissle and other strains were streaked onto agar plates and placed in (A) 0.04% CO<sub>2</sub>; (B) 5% CO<sub>2</sub> | + | <figcaption>Fig. 5. Confirmation of <i>can</i> knockout in <i>E. coli</i> Nissle. <i>E. coli</i> Nissle and other strains were streaked onto agar plates and placed in (A) 0.04% CO<sub>2</sub>; (B) 5% CO<sub>2</sub> conditions for phenotyping. </figcaption> |
</figure> | </figure> | ||
</div> | </div> | ||
</div> | </div> | ||
</div> | </div> | ||
| − | <p> As seen in Fig. 5, Δ<i>can</i>::CmR and Δ<i>can</i>::FRT requires a higher CO<sub>2</sub> level to survive. | + | <p> As seen in Fig. 5, Δ<i>can</i>::CmR and Δ<i>can</i>::FRT requires a higher CO<sub>2</sub> level to survive. In doing so, we have proved that we have successfully knocked out the <i>can</i> gene. </p> |
<br><br><br><br> | <br><br><br><br> | ||
</section> | </section> | ||
| Line 147: | Line 147: | ||
{{Template:NCKU_Tainan/gotop}} | {{Template:NCKU_Tainan/gotop}} | ||
{{Template:NCKU_Tainan/footer}} | {{Template:NCKU_Tainan/footer}} | ||
| − | <!-- | + | |
| + | <!-- Made with LOVE, by iGEM NCKU Tainan 2019. --> | ||
Latest revision as of 10:56, 13 December 2019
Demonstrate
After months of hard work and effort, iGEM NCKU Tainan 2019 is proud to reveal that "Oh My Gut" is now complete! Our team has spared no effort in giving their all to ensure that our project goes smoothly. With this project, we hope to achieve our vision of providing a comprehensive solution to chronic kidney disease, and also spreading awareness on the significance of p-Cresol on human health.
Blood p-Cresol Reader - CreSense
Our device, CreSense consists of three major parts: a centrifugal platform for plasma separation, a fluorescence intensity reader and a WiFi-module to monitor the fluorescence intensity online. In this section, we will demonstrate how our blood p-Cresol reader works.
Whole blood is injected into our microfluidic chip. All the user needs to do is to press a button to start the blood centrifugation. After approximately 15 minutes, the blood will be separated into two layers. Plasma will flow into the reaction chamber and react with our p-Cresol sensing bacteria. Then, the reader will show the real time fluorescence intensity reading on the LCD screen and simultaneously uploaded to an online database.
This device is meant to be placed in the diagnostic center and other healthcare service providers. However, this device is not limited to just patients who take our live therapeutic. Patients who are concerned about their health or is at a high risk of developing chronic kidney disease may also use this device as a preventative measure.
To demonstrate our engineered system works, we have made a video to explain each part of CreSense and the operating process.
▶ For HD video with subtitles, check out our YouTube channel!
Alternative Tyrosine Fermentation Pathway
iGEM NCKU Tainan 2019 engineered E. coli Nissle and introduced an alternative pathway for tyrosine in the gut by adding Tyrosine Ammonia Lyase. It converts tyrosine into a beneficial product, p-Coumaric acid. We improved the p-Coumaric acid production by changing the ribosome binding sites from Native to B0034, the conversion of tyrosine into p-Coumaric acid increase by 1.73-fold.
We then further improved the conversion of tyrosine into p-Coumaric acid by adding a tyrosine transporter (BBa_K2997000). As seen in Fig. 3, when BBa_K2997000 is added, the production of p-Coumaric acid is significantly higher than when BBa_K2998000 is not added. When tyrosine transporter is introduced into E. coli Nissle containing BBa_K2997009 and BBa_K2997010, conversion of tyrosine into p-Coumaric acid is increased by 1.44-fold and 1.31-fold respectively.
By culturing E. coli Nissle with dual plasmids containing TAL (BBa_K2997010) and tyrP (BBa_K2997009) in LB medium with different concentrations of tyrosine, we are able to prove that the TAL enzyme can specifically use tyrosine as its substrate. As seen in Fig. 4, although no significance in p-Couramic acid production in culture supplemented with 0.5 mM and 1.0 mM tyrosine, there was however an increasing trend. Furthermore, there was a significant increase when comparing culture supplemented with 1.0 mM and 2.0 mM tyrosine. We speculate that there was indeed a dose-dependent effect, but due to the limit of n-octanol extraction method was apparent.
Biosafety: can Gene Knock Out
To ensure the biosafety of our engineered E. coli Nissle, we did a phenotype test by streaking out the can gene mutant bacteria on different plates and placing them in different conditions.
As seen in Fig. 5, Δcan::CmR and Δcan::FRT requires a higher CO2 level to survive. In doing so, we have proved that we have successfully knocked out the can gene.
